Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Open Access Major ISEE Publication out in #1American Eye Journal Ophthalmology : “Intravitreal administration of avacincaptad pegol 2 mg and 4 mg led to a significant reduction of GA growth in eyes with AMD over a 12 month period. As C5 inhibition theoretically preserves C3 activity it may offer additional safety advantages. A second confirmatory pivotal clinical trial is underway to confirm the efficacy and safety of avacincaptad pegol in slowing the GA growth (GATHER2 Study).” Ssfety is key - disqualifies APLS in AMD.
$ISEE Zimura as a Rx of Wet AMD with Lucentis- “All 4 groups achieved significant gains in visual acuity at 6 months, defined as gaining greater than or equal to 3 lines of vision, or 15 ETDRS letters. The group with the highest percentage of patients achieving significant visual acuity gains (60%) was the group that received .5 mg of Lucentis and 2 mg of Zimura on the same day. This was the same dosing group that achieved the highest success rates in the previous 1/2a trial of Zimura. Other dosing groups had the 2 drugs staggered or had the 2 drugs in combination with a follow-up dose of Zimura only at 2 weeks.” *
so 2 points- 1. It helps explain why Wet AMD is 1/2 as common with $ISEE Zimura than with $APLS Pegcetacoplan. 2. $AGN needs a new Wet AMD treatmeNT- makes $ISEE a more likely target for GA, Wet AMD, and Gene therapy.
ISEE will get past 52 week high, lots of, lots of cash in the coffers, no issues with offerings. We could even hit 12 dollars today. Don't miss this one.